We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serum Thrombospondin-2 Levels Associated with MAFLD Severity

By LabMedica International staff writers
Posted on 31 May 2022
Print article
Image: Histopathology of metabolic associated fatty liver disease: serum thrombospondin-2 levels are associated with its severity (Photo courtesy of Endocrinology Advisor)
Image: Histopathology of metabolic associated fatty liver disease: serum thrombospondin-2 levels are associated with its severity (Photo courtesy of Endocrinology Advisor)

Metabolic associated fatty liver disease (MAFLD), previously termed non-alcoholic fatty liver disease (NAFLD), has emerged as the most common cause of liver disease globally. With the expanding epidemic of obesity worldwide, MAFLD is becoming an increasingly burdensome condition, both clinically and economically.

Thrombospondins are a family of multidomain and secretory glycoproteins. Among them, thrombospondin 2 (TSP2) encoded by the TSP2 gene has been reported to be involved in various functions such as collagen/fibrin formation, maintenance of normal blood vessel density and cell adhesion properties.

A large team of medical scientists from The University of Hong Kong (Hong Kong, China) and their colleagues investigated the associations of serum thrombospondin-2 (TSP2) with obesity-related metabolic syndrome (MetS) and MAFLD severity, and the potential diagnostic value of serum TSP2 for identifying at-risk metabolic associated steatohepatitis (at-risk MASH).

The team collected blood samples, clinical data, and liver biopsies from consecutively recruited 252 individuals with morbid obesity receiving bariatric surgery. Histopathologies of liver biopsies were examined in a blinded fashion by three independent pathologists. Serum TSP2 levels were measured by enzyme-linked immunosorbent assay (ELISA).

The scientists reported that serum TSP2 levels were significantly elevated in MetS (1.58 [1.07-2.20] ng/mL) compared with non-MetS (1.28 [0.84-1.73] ng/mL) in obese patients and positively correlated with increasing number of the MetS components, fasting glucose, HbA1c, fasting insulin, C-peptide, HOMA-IR after adjustment of conventional confounders.

Serum TSP2 levels differentiated MASH (1.74 [1.32-3.09] ng/mL) from the other non-MASH less severe groups normal liver (1.41 [1.04-1.63] ng/mL), simple steatosis (1.45 [0.89-1.92] ng/mL) and borderline MASH (1.30 [0.99-2.17] ng/mL). Elevated serum TSP2 was positively associated with the severity of hepatic steatosis, inflammation, fibrosis, and abnormal liver function independent of age, sex and adiposity. Furthermore, high serum TSP2 identified at-risk MASH with AUC of 0.84.

The authors concluded that serum TSP2 is closely associated with severity and progression of MetS and MAFLD, and is a promising noninvasive biomarker for differentiating MASH from benign steatosis and identifying at-risk MASH patients among individuals with obesity. The study was published on May 9, 2022 in The Journal Of Clinical Endocrinology And Metabolism.

Related Links:
The University of Hong Kong 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Silver Member
HPV Molecular Controls
ZeptoMetrix® HPV Type 16, 18, 45 & 68 Molecular Controls

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.